Efficacy and safety of chimeric antigen receptor T-cell therapy for plasma cell leukemia

Lignende værker

• Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
  af: Surbhi Sidana, et al.
  Udgivet: (2023-09-01)
• Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
  af: Christopher J. Ferreri, et al.
  Udgivet: (2023-08-01)
• Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
  af: Hamza Hashmi, et al.
  Udgivet: (2023-10-01)
• Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
  af: Aimaz Afrough, et al.
  Udgivet: (2024-04-01)
• Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
  af: Al‐Ola Abdallah, et al.
  Udgivet: (2021-11-01)